Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Yes, the FDA approved valproic acid oral solution for both monotherapy and adjunctive therapy to treat complex partial seizures.
A 2024 trial found that a sequenced care pathway was not superior to a pain navigator for Veterans with low back pain at 3 months.
About 48% of breast cancer patients experience chemotherapy-induced nausea and vomiting, with higher risk in younger patients and those with motion sickness history.
Yes, valproic acid oral solution is FDA-approved to be used alone for complex partial seizures.
5-HT3 antagonists and dexamethasone are both effective for CINV, but adding a 5-HT3 antagonist to dexamethasone improves outcomes; guidelines recommend using them together with…
Yes, photobiomodulation significantly reduces the risk of severe oral mucositis in head and neck cancer patients, with a 54% risk reduction shown in a recent meta-analysis.
Yes, Focinvez (fosaprepitant) is FDA-approved to prevent chemotherapy-induced nausea and vomiting when used with other antiemetics.
Propolis dry extract is the optimal treatment specifically for preventing moderate-to-severe oral mucositis in breast cancer patients, though zinc is better for overall prevention.
Key risk factors for CINV in breast cancer include younger age (≤45 years), history of motion sickness, and multiple chemotherapy cycles (≥3).
Zinc supplements were most effective for reducing overall oral mucositis in breast cancer patients, based on a network meta-analysis of 10 RCTs.
Yes, unilateral selective laser trabeculoplasty (SLT) can lower IOP in the untreated eye, with a mean reduction of about 1.85 mmHg at 3-6 months.
Yes, zinc supplements may help prevent oral mucositis after chemoradiotherapy, especially when started early and used topically, but evidence is limited.
Yes, photobiomodulation therapy is effective for reducing oral mucositis in cancer patients, with studies showing about a 50% reduction in risk.
Yes, the FDA approved nintedanib capsules for treating idiopathic pulmonary fibrosis in adults in 2014.
Genetic risk tests for idiopathic pulmonary fibrosis work best for people of European ancestry, but they show limited accuracy for non-European groups because most studies have…
Yes, obinutuzumab has helped some women with nephrotic syndrome achieve remission after rituximab failed, based on several case reports.
For high-risk NMIBC, BCG plus mitomycin does not improve disease-free survival compared to BCG alone, and may increase toxicity.
Yes, obinutuzumab and venetoclax can resolve nephrotic syndrome in CLL patients, based on case reports showing complete remission within weeks to months.
A case report shows obinutuzumab led to complete remission of nephrotic syndrome in a 76-year-old with podocytopathy, but more research is needed.
Yes, serum sickness is a possible side effect of rituximab in nephrotic syndrome patients, with symptoms like joint pain, fever, and rash typically appearing about 7 days after…
For intermediate-risk NMIBC, BCG and epirubicin show comparable recurrence and progression rates, but BCG may provide a longer time to recurrence.
Adding mitomycin to BCG does not improve disease-free survival for high-risk non-muscle invasive bladder cancer compared to BCG alone.
Intravesical gemcitabine/docetaxel may offer similar or better recurrence-free survival with fewer side effects compared to BCG for non-muscle invasive bladder cancer, but…
Adding iron to methylphenidate helps children with severe ADHD and iron deficiency respond faster to treatment compared to methylphenidate alone.
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.